SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

SMS Lifesciences India trades jubilantly on receiving EIR with VAI for Telangana facility

16 Jul 2025 Evaluate

SMS Lifesciences is currently trading at Rs. 1275.15, up by 131.35 points or 11.48% from its previous closing of Rs. 1143.80 on the BSE.

The scrip opened at Rs. 1184.80 and has touched a high and low of Rs. 1372.55 and Rs. 1179.30 respectively. So far 5909 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 1747.85 on 09-Sep-2024 and a 52 week low of Rs. 765.00 on 25-Jul-2024.

Last one week high and low of the scrip stood at Rs. 1225.95 and Rs. 1058.00 respectively. The current market cap of the company is Rs. 383.29 crore.

The promoters holding in the company stood at 71.41% while Non-Institutions held 28.59% in the company. 

SMS Lifesciences India has received establishment inspection report (EIR) with a voluntary action indicated (VAI) status from the U.S. Food and Drug Administration (USFDA) for its API manufacturing facility (Unit 1) located at Kazipally, Telangana, on July 15, 2025. The receipt of EIR reaffirms the company’s commitment to maintaining global quality standards and enables access to the regulated US market and other highly regulated global markets.

SMS Lifesciences India is presently engaged in the business of manufacturing, buying, selling, offering consultancy, importing and exporting, acting as commission agents and generally dealing with of all types of Organic & Inorganic Chemicals, Pharmaceuticals, API and Intermediates.

Haleos Labs Share Price

1300.00 1.00 (0.08%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×